The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix

Tumor Biology

Volumn 19, Issue 6, 1998, Pages 505-516

  De Bruijn, H W A ^a   Duk, J M ^a   Van der Zee, A G J ^a   Pras, E ^a   Willemse, P H B ^a   Boonstra, H ^a   Hollema, H ^a   Mourits, M J E ^a   De Vries, E G E ^a   Aalders, J G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cervical carcinoma; Squamous cell carcinoma antigen

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; FLUOROURACIL; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; CONFERENCE PAPER; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 7844237503     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030044     Document Type: Conference Paper

References (66)

1. Suminami Y, Kishi F, Segikuchi K, Kato H: Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem Biophys Res Commun 1991;181:51-58.
2. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA: A serine protease inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 1995;92:3147-3151.
3. Barnes RC, Worral DM. Identification of a novel human serpin gene; cloning sequencing and expression of leupin. FEES Lett 1995;373:61-65.
4. Hoshina M, Kimura A, Shibata K, Marao T, Mochizuki M: Immunocytochemical distribution of the tumor antigen TA-4: Expression during carcinogenesis and maturation of squamous epithelium of human uterine cervix. Asia Oceania J Obstet Gynaecol 1986;12:119-126.
5. Maruo T, Shibata K, Kimura A, Hoshina M, Mochizuki M: Tumor associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization. Cancer 1985;56:302-308.
6. Kato H, Miyauchi F, Morioka H, Fujino T, Torigoe T: Tumor antigen of human cervical squamous cell carcinoma. Correlation of circulating levels with disease progress. Cancer 1979;43:585-590.
7. Kato H, Morioka M, Tsutsui H, Aramaki S, Torigoe T: Value of tumor-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 1982;50:1294-1296.
8. Kato H, Morioka H, Aramaki S, Tamai S, Torigoe T: Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Am J Obstet Gynecol 1983;145:350-354.
9. Kato H, Tamai K, Moriaka H, Magai M, Nagaya T, Torigoe T: Tumour antigen, TA-4, in the detection of recurrence in cervical squamous cell carcinoma. Cancer 1984;54:1544-1546.
10. Ferenczy A, Winkler B: Carcinoma and metastatic tumors of the cervix; in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract. New York, Springer, 1987, pp 218-257.
11. Creasman WT: New cervical cancer staging. Gynecol Oncol 1995;58:157-158.
12. Duk JM, Groenier KH, De Bruijn HWA, Hollema H, Ten Hoor KA, Van Der Zee AGJ, Aalders JG: Pretreatment serum SCC antigen: A new prognostic factor in early stage cervical carcinoma. J Clin Oncol 1996;14:111-118.
13. Pras E, Willemse PHB, Boonstra H, Hollema H, Heesters MAAH, Szabó BG, De Bruijn HWA, Aalders JG, De Vries EGE: Concurrent chemoand radiotherapy in patients with locally advanced carcinoma of the cervix. Ann Oncol 1996;7:511-516.
14. Kato H, Suehiro Y, Morioka H: Heterogeneous distribution of acidic TA-4 in cervical squamous cell carcinoma; immunohistochemical demonstration with monoclonal antibodies. Gann 1987;78:1246-1250.
15. Tsuyama S, Hashimoto K, Nakamura K, Tamura H, Sasaki K, Kato H: Different behaviour in the production and release of SCC antigen in squamous cell carcinoma. Tumor Biol 1991;12:28-34.
16. Kato H: Squamous cell carcinoma antigen; in Sell S (ed): Serological Cancer Markers. Totowa, Humana Press, 1992, pp 437-451.
17. Suehiro Y, Kato H, Nagai M, Torigoe T: Flow cytometric analysis of tumor antigen TA-4 in cervical cytologic specimen. Cancer 1986;57:1380-1384.
18. Crombach G, Würz H, Herrmann F, Kreienberg R, Möbus V, Schmidt-Rode P, Sturm G, Caffier H, Kaesemann H: Bedeutung des SCC-Antigens in der Diagnostik und Verlaufskontrolle des Zervix-karzinoms. Dtsch Med Wochenschr 1989;114:700-705.
19. Beynon DWG, Lopes A, Robertson G, Daras V, Monaghan JM: Squamous cell carcinoma antigen: Pretreatment levels as an indicator of advanced or metastatic disease. Int J Gynecol Cancer 1994;4:206-210.
20. Bolger BS, Dabbas M, Lopes A, Monaghan JM: Prognostic value of pre-operative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 1997;65:309-313.
21. Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB, Winchester WP, Clive RE: Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma of the cervix? Cancer 1995;76/S10:1948-1955.
22. Duk MJ, De Bruijn HWA, Groenier KH, Hollema H, Ten Hoor KA, Krans M, Aalders JG: Cancer of the uterine cervix, sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 1990;39:186-194.
23. Åvall-Lundqvist EH, Sjovall K, Nilsson BR, Eneroth PHE: Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer 1992;28A:1695-1702.
24. Scambia G, Benedetti Panici P, Foti E, Amoroso M, Salerno G, Ferrandina G, Battaglia F, Greggi S, De Gaetano A, Puglia G, Mancuso S: Squamous cell carcinoma antigen: Prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 1994;12:2309-2316.
25. Chou CY, Wang ST, Kuo HC, Tzeng CC, Yao BL: Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer 1994;74:2497-2501.
26. Sproston ARM, Roberts SA, Davidson SE, Hunter RD, West CML: Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Br J Cancer 1995;72:1536-1540.
27. Takeda A, Yamamoto T, Nakamura Y, Takahashi T, Hibino T: Squamous cell carcinoma antigen is a potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett 1995;359:78-80.
28. Nawata S, Tsunaga N, Numa F, Tanaka T, Nakamura K, Kato H: Serine protease inhibitor activity of recombinant squamous cell carcinoma antigen towards chymotrypsin, as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 1995;16:1027-1030.
29. Foekens JA, Schmitt M, van Putten JWL, Peters HA, Kramer MD, Jänicke F, Klijn JMG: Plasminogen activator inhibitor-1 and breast cancer prognosis. J Clin Oncol 1994;12:1648-1658.
30. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-618.
31. Kato H, de Bruijn HWA, Ebert W, Herberman RB, Johnson JT: SCC Antigen in the Management of Squamous Cell Carcinoma. Princetown, Excerpta Medica, 1987, p 239.
32. Kato H: Studies on the special tumor marker of cervical cancer of the uterus. Semin Surg Oncol 1987;3:55-63.
33. Senekjian EJ, Maitland Young J, Weiser PA, Spencer CE, Magic SE, Herbst A: An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol 1987;157:433-439.
34. De Bruijn HWA. Bouma J, Krans M, Boonstra H, Van der Sijde R, Aalders JG: Serum SCC, a useful tumor marker in patients with squamous cell carcinoma of the cervix; in Kato H, De Bruijn HWA, Ebert W, Herberman RB, Johnson JT (eds): SCC Antigen in the Management of Squamous Cell Carcinoma. Princetown, Excerpta Medica, 1987, pp 18-33.
35. Crombach G, Wuerz H: Serum concentrations of SCC antigen in patients with cervical cancer, in Kato H, de Bruijn HWA, Ebert W, Herberman RB, Johnson JT (eds): SCC Antigen in the Management of Squamous Cell Carcinoma. Princetown, Excerpta Medica, 1987, pp 54-63.
36. Kenter G, Bonfrer JMG, Heintz APM: Pretreatment tumour antigen Ta-4 in serum of patients with squamous cell carcinoma of the uterine cervix. Br J Cancer 1987;56:157-158
37. Schmidt-Rohde P, Schulz KD, Sturm G, Häfner H, Prinz H, Künzig HJ: Squamous cell carcinoma antigen for monitoring cervical cancer. Int J Cancer 1988;3:87-94.
38. Maiman M, Feuer G, Fruchter R, Shaw N, Boyce J: Value of squamous cell carcinoma antigen levels in invasive cervical cancer. Gynecol Oncol 1989;34:312-316.
39. Ngan HYS, Wong LC, Chan SYW. Ma HK: Use of the serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer. Gynecol Oncol 1989;35:259-262.
40. Holloway RW, To A, Moradi M, Boots L, Watson N, Shingleton H: Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay. Obstet Gynecol 1989;74:944-949.
41. Dodd JK, Henry RJW, Tyler JPP, Houghton CRS: Cervical carcinoma: Comparison of four potential biochemical tumor markers. Gynecol Oncol 1989;32:248-252.
42. Meier W, Eiermann W, Stieber P, Fateh-Moghadam A, Schneider A, Hepp H: Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy. Gynecol Oncol 1990;38:6-11.
43. Molina R, Fillela X, Torres MD, Ballesta AM, Mengual P, Cases A, Balaque A: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990;36:251-254.
44. Ngan HYS, Chan SYW, Wong LC, Choy DTK, Ma HK: Serum squamous cell carcinoma antigen assays in the monitoring of radiotherapy response in carcinoma of the cervix. Gynecol Oncol 1990;37:260-263.
45. Lehtovirta P, Viinikka L, Ylikorkala O: Comparison between squamous cell carcinoma-associated antigen and CA 125 in patients with carcinoma of the cervix. Gynecol Oncol 1990;37:276-278.
46. Brioschi PA, Bischof P, Delafosse C, Krauer F: Squamous cell carcinoma antigen values related to clinical outcome of pre-invasive and invasive cervical cancer. Int J Cancer 1991;47:376-379.
47. Scambia G, Beneditti Panici P, Biaocchi G, Amoroso M, Foti E, Greggi S, Mancuso S: The value of squamous cell carcinoma antigen in patients with localy advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 1991;164:631-636.
48. Verlooy H, Devos P, Janssens J, Mortelmans L, Gertis M, Bonte J: Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Gynecol Obstet Invest 1991;32:55-58.
49. Yazigi R, Munoz A, Richardson B, Risser R: Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer. Gynecol Oncol 1991;41:135-138.
50. Leminen A, Alftan H, Stenman UH, Lehtovirta P: Chemotherapy as initial treatment for cervical carcinoma: Clinical and tumor marker response. Acta Obstet Gynecol Scand 1992;71:293-297.
51. Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE: Serum squamous cell carcinoma antigen levels in invasive cervical cancer: Prediction of response and recurrence. Am J Obstet Gynecol 1993;168.942-946.
52. Bolli JAN, Doering DL, Bosscher JR, Day TG, Rao CV, Owes K, Kelly B, Goldsmith J: Squamous cell carcinoma antigen: Clinical utility in squamous cell carcinoma of the cervix. Gynecol Oncol 1994;55:169-173.
53. Stenman J, Lintula S, Hotakainen K, Vartiainen J, Lehväslaiho H, Stenman UH: Detection of squamous cell carcinoma antigen-expressing tumour cells in blood by reverse transcriptase-polymerase chain reaction in cancer of the uterine cervix. Int J Cancer 1997;74:75-80.
54. Ferdeghini M, Gadducci A, Annicchiarico C, Prontera C, Malagnino G, Castellani C, Fachini V, Bianchi R: Serum Cyfra 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res 1993;13:1841-1844.
55. Gaarenstroom KN, Bonfrer JMG, Kenter GC, Korse CM, Hart AAM, Trimbos JB, Helmerhorst TJM: Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 1995;76:807-813.
56. Ansink A, de Barro Lopes A, Naik R, Monaghan JM: Recurrent stage Ib cervical carcinoma: Evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol 1996;103:1156-1158.
57. Alberts DS, Garcia D, Mason-Lidill N: Cisplatin in advanced cancer of the cervix: An update. Semin Oncol 1991,18(suppl3):11-24.
58. Vermerken JB: The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review. Int J Gynecol Cancer 1993;3:129-142.
59. Duk JM, van Voorst Vader PC, ten Hoor KA, Hollema H, Doeglas HMG, de Bruijn HWA: Elevated levels of squamous cell carcinoma antigen in patients with benign disease of the skin. Cancer 1989;64:1652-1656.
60. Mino M, Lio A, Hamamoto K: Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer 1988;62:730-734.
61. Body JJ, Sculier JP, Raymakers N, Paesmans M, Ravez P, Libert P, Richez M, Dabouis G, Lacrouix H, Bureau G, Thiriaux J, Lecomte J, Brotée D, Mommen P, Frilling J, Klastersky J: Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 1990;65:1552-1556.
62. Fischbach W, Rink C: SCC-Antigen: ein sensitiver and spezifischer Tumormarker für Plattenkarzinome? Dtsch Med Wochenschr 1988;113:289-293.
63. Fischbach W, Maier T, Barthel K: Squamous cell carcinoma antigen in the diagnosis and follow-up of oral and facial squamous cell carcinoma. Cancer 1990;65:1321-1324.
64. Yagi H, Danno K, Maruguchi Y: Significance of squamous cell carcinoma (SCC)-related antigen in cutaneous SCC. A preliminary report. Arch Dermatol 1987;123:902-906.
65. Duk MJ, Aalders JG, Fleuren GJ, Krans M, De Bruijn HWA: Tumor markers CA 125, SCC and CEA in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol 1989;73:661-668
66. Duk JM, De Bruijn HWA, Groenier KH, Fleuren GJ, Aalders JG: Adenocarcinoma of the cervix. The prognostic significance of pretreatment serum CA 125, SCC and CEA levels in relation to clinical and histopathological tumour characteristics. Cancer 1990;65:1830-1837.